Arctic Bioscience AS

Arctic Bioscience AS Net Debt per Share

The Net Debt per Share of Arctic Bioscience AS (ABS.OL) as of Nov 4, 2026 is 1.01 NOK. In the previous year, Net Debt per Share was 1.14 NOK — a change of -10.90% (lower).

Net Debt per Share

1.01NOK

YoY

-10.90%

Last updated:

Net Debt per Share of Arctic Bioscience AS is 2025 1.01 NOK. Net Debt per Share of Arctic Bioscience AS was 2024 1.14 NOK. It decreases by -10.90% lower compared to the previous year.

The Arctic Bioscience AS Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2018
0.43 NOK
Jan 1, 2019
-0.60 NOK
Jan 1, 2020
-0.15 NOK
Jan 1, 2021
-8.43 NOK
Jan 1, 2022
-5.31 NOK
Jan 1, 2023
-2.88 NOK
Jan 1, 2024
1.14 NOK
Jan 1, 2025
1.01 NOK
The Arctic Bioscience AS Net Debt per Share history
YEARNet Debt per ShareYoY
1.01NOK-10.90%
1.14NOK-139.58%
-2.88NOK-45.79%
-5.31NOK-37.08%
-8.43NOK+5,385.57%
-0.15NOK-74.50%
-0.60NOK-239.00%
0.43NOK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arctic Bioscience AS Stock analysis

What does Arctic Bioscience AS do? Arctic Bioscience AS develops marine ingredients from herring roe for autoimmune disorder therapies, focusing on HRO350 for psoriasis treatment. The company markets B2B products like herring caviar oil and protein through subsidiaries such as Arctic Nutrition AS and Romega AS, which produces omega-3 supplements in capsule form. Its product Romega targets consumers seeking dietary supplements, while B2B segments buy herring roe-derived ingredients for further processing. The firm's subsidiaries handle distinct segments: Arctic Nutrition AS focuses on nutritional products, Romega AS on dietary supplements, and Arctic Biopharma AS on drug development. Arctic Bioscience AS generates revenue through B2B sales of herring caviar oil and protein, alongside consumer sales of Romega omega-3 capsules. HRO350 remains in development but is positioned for future therapeutic sales. Subsidiaries like Romega AS directly serve end-users with dietary supplements, while Arctic Nutrition AS and Arctic Biopharma AS support B2B and clinical development needs. The company’s strategy aligns with its purpose of providing marine membrane lipid-based therapies for autoimmune conditions. The firm’s revenue streams include Romega’s omega-3 dietary supplements sold to consumers and herring caviar oil/protein sold to businesses. Arctic Nutrition AS and Romega AS operate within the B2B and consumer markets, respectively, while Arctic Biopharma AS develops HRO350 for psoriasis treatment. All products derive from herring roe extraction, with no additional brands or products mentioned in the business description. Arctic Bioscience AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arctic Bioscience AS stock

Net Debt per Share of Arctic Bioscience AS is 1.01 NOK in 2025.

Net Debt per Share of Arctic Bioscience AS changed from 1.14 NOK to 1.01 NOK, representing a -10.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share Arctic Bioscience AS since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Arctic Bioscience AS

All Key Metrics — Arctic Bioscience AS